| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD226 |
| Uniprot No | Q15762 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-247aa |
| 氨基酸序列 | EEVLWHTSVPFAENMSLECVYPSMGILTQVEWFKIGTQQDSIAIFSPTHG MVIRKPYAERVYFLNSTMASNNMTLFFRNASEDDVGYYSCSLYTYPQGTW QKVIQVVQSDSFEAAVPSNSHIVSEPGKNVTLTCQPQMTWPVQAVRWEKI QPRQIDLLTYCNLVHGRNFTSKFPRQIVSNCSHGRWSVIVIPDVTVSDSG LYRCYLQASAGENETFVMRLTVAEGKTDN |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD226重组蛋白的3篇参考文献的简要整理(基于模拟学术文献内容，仅供示例参考)：
---
1. **标题**：*Structural and functional analysis of CD226 (DNAM-1) interaction with ligand PVR*
**作者**：Shibuya, A., et al.
**摘要**：研究通过重组CD226蛋白的体外结合实验，揭示了CD226与配体PVR(脊髓灰质炎病毒受体)的特异性相互作用，并证明其在NK细胞和T细胞介导的肿瘤免疫监视中的关键作用。
2. **标题**：*Recombinant CD226 extracellular domain inhibits tumor growth by blocking immune checkpoint pathways*
**作者**：Wang, Y., et al.
**摘要**：利用重组CD226胞外域蛋白进行小鼠模型实验，发现其可通过竞争性阻断CD226-PVR/Nectin-2通路，增强抗肿瘤免疫反应，为癌症免疫治疗提供新策略。
3. **标题**：*CD226 glycosylation modulates its binding affinity to ligands: Insights from recombinant protein mutagenesis*
**作者**：Chen, L., et al.
**摘要**：通过重组CD226蛋白的糖基化位点突变体研究，发现糖基化修饰显著影响CD226与配体的结合能力，为设计靶向免疫调节分子提供结构依据。
---
**注**：以上文献为模拟内容，实际研究中建议通过PubMed、Web of Science等数据库检索真实文献。如需具体论文，可提供更详细的研究方向或应用场景进一步筛选。
CD226 (also known as DNAM-1) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on immune cells such as T cells, natural killer (NK) cells, and platelets. It plays a critical role in regulating immune responses by interacting with its ligands CD155 (PVR) and CD112 (nectin-2), which are often overexpressed on tumor cells or virus-infected cells. This interaction facilitates immune cell adhesion, activation, and cytotoxic activity, positioning CD226 as a key player in immune surveillance and anti-tumor immunity.
Recombinant CD226 protein is engineered to mimic the extracellular domain of the native protein, typically produced in mammalian expression systems to ensure proper glycosylation and structural fidelity. This soluble form retains ligand-binding capacity and is widely used in functional studies to elucidate CD226-mediated signaling pathways, ligand-receptor interactions, and cross-talk with co-inhibitory receptors like TIGIT and CD96. Such research highlights CD226’s dual role: it synergizes with activating receptors (e.g., CD16. TCR) to enhance cytotoxicity while competing with inhibitory receptors for shared ligands, balancing immune activation and tolerance.
Therapeutic applications of recombinant CD226 protein include its use in blocking/activating assays to develop cancer immunotherapies. For instance, it may serve as a decoy receptor to inhibit ligand-mediated immunosuppression or as a tool to engineer CD226-enhancing therapies. Additionally, it aids in biomarker discovery for diseases linked to CD226 dysregulation, such as autoimmune disorders (e.g., rheumatoid arthritis) and viral infections (e.g., COVID-19), where CD226 polymorphisms correlate with disease susceptibility.
Overall, recombinant CD226 protein is a vital reagent for dissecting immune regulation mechanisms and advancing translational research in oncology and immunotherapy.
×
